LDS/Medical Tests/ToRCH Panel, IgM

ToRCH Panel, IgM

The TORCH panel is used to prenatally screen for prevention of neonatal infectious diseases. The TORCH panel includes Toxoplasmosis, Other, Rubella, Cytomegalovirus (CMV), and Herpes Symplex Virus (HSV). Other infections that can be included are syphilis, HIV, parvovirus B19, hepatitis B, varicella, and enterovirus. Since the immune system is not fully developed in infants, screening for detection of these infectious agents is performed to prevent infection in newborn. If infants are infected with one or more of these infectious agents, severe disease can develop. Symptoms can include: low birth weight, rash, jaundice, and hepatosplenomegaly. Hearing loss or mild mental retardation later in life can also manifest from these congenital infections. The TORCH panel may include the following:

Toxoplasma gondii IgG and IgM:

In pregnant women, T. gondii infection poses a potential threat to the fetus. The earlier in the pregnancy that the mother is infected the greater the potential severity of congenital toxoplasmosis. If the fetus becomes infected, the infant may have symptoms such as lymphadenopathy, chorioretinitis, microcephaly, and cerebral calcifications. Because isolation of the organism is difficult, toxoplasma IgM assays have been used in conjunction with clinical information in the diagnosis of T. gondii infection.  Screening for infection is usually performed at 12 months. A positive toxoplasma IgG test in early pregnancy indicates that the patient was exposed to toxoplasmosis in the past and is now immune. A positive IgM test may indicate active disease. Serial testing demonstrating four-fold rise in IgG titer or the appearance of IgM antibodies may indicate acute infection.

Rubella IgG and IgM:

The rubella virus is a single-stranded enveloped RNA virus. In infants and children, the virus is the cause of the usually self-limiting disease known as German measles. Before widespread vaccination, German measles was mainly a disease of young children; however, today it is mainly seen in young unvaccinated adults. Symptoms include fever, malaise, coryza, lymphadenopathy, and a fine maculopapular rash. When present, the rash usually develops rapidly within a day and fades in two to three days. The infection usually resolves without complications within 1-2 weeks; however, it is recommended that all women of childbearing age be tested for antibodies to the rubella virus because viral infection during the first trimester of pregnancy can result in birth defects. The virus can cross the placenta and cause destruction to the fetal capillaries. Children infected in utero can be born with cataracts, glaucoma, deafness, heart defect, bone disease, or neurological problems. Antibodies to rubella can be detected by hemagglutination inhibition (HI), complement fixation (CF), indirect hemagglutination (IHA), ELISA, or latex agglutination (LA).

Cytomegalovirus IgG and IgM:

CMV infection is the most common life-threatening opportunistic infection in immuno-compromised patients and neonates. Congenital CMV infection is probably the most common infectious cause of mental retardation and deafness in children.  Infection in immunocompetent individuals usually results in mononucleosis similar to infection with Epstein-Barr virus.  Testing for CMV antibody is performed to evaluate immune status to CMV in pregnant women and newborns in conjunction with other TORCH panel elements. The presence of IgM may indicate current infection, but IgM antibodies may persist for years after initial exposure. IgG antibody titers fluctuate in normal individuals, but a four-fold or greater rise in titer between acute and convalescent sera is indicative of infection.

Herpes Simplex:

Congenital herpes infection can cause severe disease in newborns. Testing for congenital herpes is usually performed as a screening test in pregnant women having a history of herpes infection or in pregnant women with a higher risk of herpes infection. Screening is usually performed by testing for HSV 1 and HSV 2 IgG antibody. If positive, delivery by Caesarean section can be offered. Pregnant women and newborns can also be screened for HSV by PCR if indicated. Culture can be also performed but results can take days to weeks.

HIV-1 & HIV-2 Antibody Screen:

Human immunodeficiency virus type 1 (HIV-1) has been identified as the primary cause of acquired immunodeficiency syndrome (AIDS). In 1986 human immunodeficiency virus type 2 (HIV-2) was isolated from an AIDS patient in West Africa. Both HIV-1 and HIV-2 are members of the genus Lentiviridae of the family of Retroviridae. The routes of transmission of HIV-1 and HIV-2 are the same; however, in HIV-2 infections the transmission and viral replication rate are much lower. Although the parenteral transmission mode of HIV infection remains important, the most common mode of transmission is sexual. Viremia occurs in 4 to 11 days with RNA levels often in excess of 1,000,000 copies per mL. Seroconversion usually occurs within 2 to 6 weeks after exposure to infection, although it may occur earlier or much later in some cases. The enhanced third-generation antigen sandwich assay for screening for HIV infection is a very sensitive and specific assay now in use. This assay detects antibody to HIV-1, HIV-2, and HIV-O (Group O) earlier than previous generations of tests. Sera which are repeatedly reactive in two out of three tests are subject to confirmatory testing by the Western blot method or other confirmatory testing. Patients with indeterminate results should be retested 30 days later and again 2 to 5 months later if still indeterminate.

Syphilis:

Syphilis is a sexually transmitted infection (STI) caused by the spirochete Treponema pallidum. Syphilis can be divided into three infectious stages; primary, secondary, and early latent, and two non-infectious disease stages: late latent and tertiary.

During infection, a broad immune response is produced that consists of anti-treponemal and non-specific (cardiolipin) antibodies. During primary syphilis, treponemal IgM may be detected within approximately two weeks post-infection and IgG after about four weeks. Antibodies can usually be detected by the time clinical symptoms appear.  Currently, two types of assays are used for diagnosis of syphilis: nontreponemal antibody testing and treponemal antibody testing. The nontreponemal tests for syphilis in use today are flocculation tests using the basic antigen formula of the Venereal Disease Research Laboratory (VDRL) test, which contains cardiolipin, cholesterol, and lecithin. The rapid plasma reagin (RPR) test uses a stabilized suspension to which charcoal particles have been added. These tests are not very sensitive. The treponemal antibody tests are antibody-based tests that detect specific antibody to T. pallidum.

Parvoviros Serology (B19):

Parvovirus B19 (B19) is a highly contagious human-acquired DNA virus of the Parvoviridae family. It is the causative pathogen of a common childhood ailment, known as Fifth Disease (erythema infectiosum) that causes a red rash on the face. It is generally a mild disease and requires little treatment if the patient is not immunocompromised. Immunocompromised adults can also be infected with Parvovirus B19, causing similar symptoms, but can also include joint swelling and pain that is usually self-limited. Parvovirus B19 can also cause severe anemia in patients who require a continual rapid production of red blood cells such as those with sickle cell anemia, red blood cell enzymopathies, and autoimmune hemolytic anemia. 50% of adults have been exposed to the virus and are immune. B19 virus infection is usually acquired by direct contact with respiratory droplets from infected individuals. During pregnancy, B19 virus may be transmitted to the fetus resulting in hydrops fetalis and intrauterine death. There is no vaccination for Parvovirus B19, so prevention is most important. Immunity status and/or past infection can be determined from Parvovirus B19 antibody testing. Determination of B19 virus titers or acute/convalescent samples can provide significant clinical information in the assessment of individuals with suspected B19 virus infection. The presence of Parvovirus B19 IgM antibodies indicates recent infection and the presence of IgG antibodies indicates immunity or past exposure.

Toxoplasma IgG and IgM:

  • Diagnosis of toxoplasmosis
  • Differential diagnosis of acute, recent, or reactivated toxoplasma infection
  • Evaluation of immunity to toxoplasma
  • Screening pregnant women and newborns for toxoplasma infection

Rubella IgG and IgM:

  • Diagnosis of rubella infection
  • Prenatal screening for congenital rubella syndrome
  • Aid in the assessment of immune status of rubella

Cytomegalovirus IgG and IgM:

  • Diagnosis of CMV infection
  • Evaluation of CMV immune status in transplant patients
  • Evaluation of CMV immune status in pregnant women
  • Diagnosis of active or reactivated infection in HIV patients
  • Assessment of preemptive or prophylactic anti-CMV specific antiviral treatment in transplant patients
  • Monitoring response to CMV-specific antiviral therapy
  • Diagnosis of CMV infection in newborn and other diseases related to CMV infection in immunocompromised patients
  • Assessing CMV status in blood donors

Herpes Simplex Virus 1 and 2 IgM:

  • Diagnosis of HSV infection (acute or persistent infection)
  • Screening for infection during pregnancy
  • Diagnosis of HSV infection in a patient who is exhibiting symptoms or in a patient who has recent exposure but has yet to show symptoms

Herpes SImplex Virus 1 and 2 IgG:

  • Screening during pregnancy
  • Screening of organ transplant recipients for infection
  • Screening of immunocompromised patients for infection
  • Screening of asymptomatic patients exposed to a partner with HSV infection
  • Screening of patients with high risk of STD

HIV-1 & HIV-2 Antibody Screen:

  • Screening for human immunodeficiency virus antibody type 1 and type 2
  • Blood and tissue donor screening for human immunodeficiency virus antibody type 1 and type 2
  • Follow-up on those exposed with the initial negative testing (CDC recommendations) after 1, 3, 6, and 12 months

Syphilis:

  • As an aid in the diagnosis of active T. pallidum infection
  • Differential diagnosis of active infection/disease

Parvovirus B19 IgG and IgM:

  • Serological determination of past, recent, or current infection with B19 virus
  • Assessment of serological status to B19 in pregnant women and others at risk including immunocompromised individuals
  • Diagnosis of fifth disease (erythema infectiosum)

Toxoplasma IgG and IgM:

Increased in:

  • Toxoplasma infection (acute, recent, or reactivation)
  • If IgM and IgG are positive it might indicate acute or persistent infection
  • If only IgM is positive and IgG negative it might indicate acute infection. Culture or toxoplasma by PCR should be ordered to confirm infection. Because false positive results can occur due to RF and ANA, patients can be retested for IgG in 2 - 4 weeks. However, if indicated, patients can be treated.
  • If IgG is positive and IgM negative, this indicates past infection or patient is immune to toxoplasma due to previous exposure. Caution should be taken in patients with suppressed immunity.
  • Since screening is performed to detect acute infection, IgM antibody must be included

Note: Antinuclear antibodies (ANA) and rheumatoid factor (RF) should also be ordered with this test because RF and ANA can cause false-positive results.

Rubella IgG and IgM:

Increased in:

  • Recent or prior rubella infection
  • Congenital rubella infection
  • Vaccination (immunity)
  • Spuriously increased IgM antibody occurs in the presence of rheumatoid factor or by cross-reacting antibodies to other viral infections or autoimmune illnesses

Cytomegalovirus IgG and IgM:

Positive in:

  • Past CMV infection, current infection (IgG is positive, IgM might be positive but often negative)
  • Recurrent infection (IgG positive, IgM might be positive or negative)
  • Acute Infection (IgM positive, IgG might be positive or negative depending on timing)
  • Infectious mononucleosis
  • Chronic fatigue syndrome

Herpes Symplex Virus 1 and 2 IgM:

Positive in:

  • In patients with acute HSV infection or reactivation

Negative in:

  • In patient with prior infection and no symptoms (lesions) of reactivation and/or non-infected patients

Herpes SImplex Virus 1 and 2 IgG:

Positive in:

  • In patients with current or past HSV infection
  • In patient with acquired immunity to HSV

Negative in:

  • Non-infected patients or in infected patients with HSV, but the sample was collected before the antibody had time to develop

HIV-1 & HIV-2 Antibody Screen:

Positive in:

  • HIV infection
  • Small but significant number of (0.1 - 0.3%) yield false-positive results in EIA, which could be caused by the binding of low-affinity natural polyreactive antibodies; this requires a western blot method for confirmation

Negative in:

  • Non-infected patients
  • Infected patients with HIV 1/2, but the sample was collected before the antibody had time to develop

Positive results should be repeated in duplicate and are subject to confirmatory testing by the western blot (WB) method or other confirmatory testing. Patients with indeterminate results by WB should be retested 30 days later and again 2 to 5 months later if still indeterminate. For individuals who are confirmed positive for antibodies, appropriate counseling and medical evaluation should be offered.

Syphilis:

Increased in:

  • T. pallidum infection
  • Syphilis active infection
  • Active syphilis disease

Parvovirus B19 IgG and IgM:

Increased or Positive for Antibody (Detected) in:

  • Recent infection (if IgM positive and IgG positive or negative)
  • Past infections (IgG positive, IgM negative)
  • Vaccination (immunity)

Decreased or Negative for Antibody (Not Detected) in:

  • Non-vaccinated patients
  • Newborn
  • Young children not exposed to virus
Test Interpretation / Reference
Toxoplasma IgG and IgM Negative (Non-reactive) or <0.9 index value
Cytomegalovirus IgG and IgM Negative (Non-reactive) or <0.9 index value
Herpes Symplex Virus 1 and 2 IgM Negative (Non-reactive) or <0.9 index value
Herpes Symplex Virus 1 and 2 IgG Negative (Non-reactive) or <0.9 index value
HIV-1 & HIV-2 Antibody Screen Negative (Non-reactive)
Syphilis Negative (Non-reactive) or <0.9 index value
Parvovirus B19 IgG and IgM Negative (Non-reactive) or <0.9 index value

 

Rubella Antibody Value Interpretation
IgG antibody <5 IU/mL Negative, not immune
5-9 IU/mL Equivocal
>10 IU/mL Positive, indicative of current, or previous exposure or immunization
IgM antibody <0.9 IV Negative, not immune
0.9 - 1.0 Equivocal
>1.0 Positive, indicative of acute or current, or exposure
Test Methodology
Toxoplasma IgG and IgM IgM antibody capture microparticle direct hemiluminometric in vitro diagnostic immunoassay
Rubella IgG and IgM Hemagglutination inhibition (HI), complement fixation (CF), indirect hemagglutination (IHA), ELISA, latex agglutination (LA)
Cytomegalovirus IgG and IgM Enzyme immunoassay, ELISA
Herpes Symplex Virus 1 and 2 IgM Chemiluminescent enzyme-labeled immunoassay, ELISA
Herpes Symplex Virus 1 and 2 IgG Hemiluminescent enzyme-labeled immunoassay, ELISA
HIV-1 & HIV-2 Antibody Screen Chemiluminescent enzyme immunoassay, ELISA
Syphilis Enzyme Immunoassay
Parvovirus B19 IgG and IgM Enzyme Immunoassay, ELISA

Toxoplasma IgG and IgM:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Rubella IgG and IgM:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Cytomegalovirus IgG and IgM:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Herpes Symplex Virus 1 and 2 IgM:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Herpes Symplex Virus 1 and 2 IgG:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

HIV-1 & HIV-2 Antibody Screen:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Syphilis:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Parvovirus B19 IgG and IgM:

Whole blood collected in EDTA lavender or purple top, or citrate, blue top tube, Serum collected in serum separated tube (SST).

Toxoplasma culture or by PCR, ANA, Rheumatoid Factor, CBC, Comprehensive metabolic panel, Glucose-6-Phosphate Deficiency Screen, Rubella DNA by PCR, CMV by PCR (for confirmation of antibody positive results especially in transplant and immunocompromised patients), CMV culture if indicated, EBV-VCA IgM, EBV-EA, EBV-VCA IgG, EBNA, HSV culture, HSV by PCR, HIV Western Blot, HIV Viral Load (HIV by RT-PCR quantitative), HIV Genotyping, CD4 count, CD8 count, CD4/CD8 ratio.

3-5 days. 

Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login